Sponsored by:THE MEDICAL EDUCATOR

CONSORTIUM

ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

August 18-20, 2017The Langham HotelPasadena, CA

Presented by the California Cancer ConsortiumUniversity of California Davis Comprehensive Cancer Center

Sacramento, caCity of Hope Comprehensive Cancer Center

Duarte, caUniversity of Southern California/Norris Comprehensive Cancer Center

LoS angeLeS, caStanford Cancer Institute Comprehensive Cancer Center

StanforD, ca

Conference Chairs:

Primo Lara, Jr., M.D. | Edward Newman, Ph.D.

Educational Steering Committee:David Gandara, M.D.

Shivaani Kummar, M.D.Heinz-Josef Lenz, M.D.

13 th“Recent Advances and New Directions in Cancer Therapy”

PROGRAM CHAIRS

Primo Lara, Jr., M.D. Acting Director, UCD ComprehensiveCancer CenterProfessor of MedicineUniversity of California Davis School of MedicineAssociate Director for Translational ResearchUniversity of California Davis Comprehensive Cancer Center

Edward Newman, Ph.D. Associate Professor, Cancer BiologyCo-Leader of the Development Cancer Therapeutics Program City of Hope Comprehensive Cancer CenterDuarte, CA

STEERING COMMITTEE

David Gandara, M.D. Professor of MedicineUniversity of California Davis School of MedicineSenior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Shivaani Kummar, M.D. Professor of MedicineStanford University School of Medicine

Heinz-Josef Lenz, M.D. Professor of Medicine and Preventive Medicine, Section Head of GI OncologyUniversity of Southern California, Keck School of MedicineAssociate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

DISTINGUISHED FACULTY Afsaneh Barzi, MD, PhDAssistant Professor of Medical Oncology Department of MedicineDivision of OncologyUSC Norris Comprehensive Cancer CenterLos Angeles, CA

Robert Chen, MD Associate ProfessorCity of Hope Medical CenterDuarte, CA

Helen Chew, MD Professor of Medicine, Division of Hematology/OncologyUC Davis Comprehensive Cancer CenterSacramento, CA

Vincent Chung, MD, FACPAssociate Clinical ProfessorCity of Hope Department of Medical OncologyDuarte, CA

A. Dimitrios Colevas, MDAssociate Professor of MedicineStanford University School of MedicineStanford, CA

Mihaela Cristea, MDAssistant Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Tanya Dorff, MDAssistant ProfessorUSC Keck School of MedicineNorris Comprehensive Cancer CenterLos Angeles, CA

Oliver Dorigo, MD, PhDProfessorStanford University School of MedicineStanford, CA

Anthony El-Khoueiry, MDAssistant ProfessorUSC California Keck School of MedicineNorris Comprehensive Cancer CenterLos Angeles, CA

Marwan Fakih, MDInterim Chair and Professor, Medical Oncology and Therapeutics ResearchSection Head, GI Medical OncologyCo-Director, GI Cancers ProgramCity of Hope Comprehensive Cancer Center Duarte, CA

Paul Frankel, PhDStaff Scientist, Division of BiostatisticsDepartment of Information SciencesBeckman Research Institute, City of Hope Comprehensive Cancer CenterDuarte, CA

David Gandara, MDProfessor of MedicineDivision of Hematology and OncologyUC Davis Comprehensive Cancer CenterSacramento, CA

Susan Groshen, PhDProfessor of Medicine and DirectorBiostatistics CoreUSC Norris Comprehensive Cancer CenterLos Angeles, CA

James Hu, MDUSC Norris Comprehensive Cancer CenterHematology/Oncology ServicesLos Angeles, CA

Brian Jonas, MD, PhDAssistant Professor, Division ofHematology/OncologyUC Davis School of MedicineSacramento, CA

Kevin Kelly, MD, PhDAssociate Professor of Clinical Medicine Assistant Medical Director of Clinical Investigations Support Office, Jane Anne Nohl Division of Hematology and Center for the Study of Blood DiseasesUniversity of Southern CaliforniaLos Angeles, CA

Edward Kim, MD, PhDAssistant Professor Division ofHematology and OncologyUC Davis Comprehensive Cancer CenterSacramento, CA

Mariana Koczywas, MDClinical Professor of MedicineCity of Hope Comprehensive Cancer CenterDuarte, CA

Shivaani Kummar, MDProfessor, Department of MedicineDirector, Phase I Clinical Research ProgramStanford University School of MedicineStanford, CA

Primo Lara, Jr., MDProfessor of Medicine, Associate Director for Translational ResearchUC Davis Comprehensive Cancer CenterSacramento, CA

Peter Lee, MDBilly Wilder Endowed ProfessorChair, Department if Immuno-OncologyCity of Hope Comprehensive Cancer CenterDuarte, CA

Heinz-Josef Lenz, MD, PhDProfessor of Medicine and Preventive MedicineSection Head of GI OncologyUniversity of Southern CaliforniaKeck School of MedicineAssociate Director for Clinical ResearchUSC Norris Comprehensive Cancer CenterLos Angeles, CA

Jeffrey Longmate, PhDProfessor and Director, Division of BiostatisticsDepartment of Information SciencesBeckman Research InstituteCity of Hope Comprehensive Cancer CenterDuarte, CA

Philip Mack, PhDAssociate Professor of Medicine, UC DavisSchool of MedicineDirector, Cancer Molecular PharmacologyUC Davis Comprehensive Cancer CenterSacramento, CA

Guido Marcucci, MDProfessor of Medicine, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Kim Margolin, MDProfessor of Medicine, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Erminia Massarelli, MD, PhDAssociate Clinical ProfessorDepartment of Medical Oncology &Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Arta Monjazeb, MD, PhDAssociate ProfessorDepartment of Radiology OncologyCity of Hope Comprehensive Cancer CenterDuarte, CA

Edward Newman, PhDAssociate Professor, Molecular PharmacologyCo-director, Analytical Pharmacology Core FacilityCity of Hope Comprehensive Cancer CenterDuarte, CA

Sumanta Pal, MDAssistant Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Mamta Parikh, MD, MSAssistant ProfessorHematology & OncologyUC Davis Comprehensive Cancer CenterSacramento, CA

Mark Pegram, MDProfessor of MedicineDirector of the Breast Cancer ProgramCo-Director of Molecular Therapeutic Program Stanford UniversityStanford, CA

Christiane Querfeld, MD, PhD, FAADChief, Division of DermatologyDirector, Cutaneous Lymphoma ProgramAssistant Professor/Dermatology/DermatopathologyCity of Hope Comprehensive Cancer CenterDuarte, CA

David Quinn, MBBS, PhDAssociate Professor and HeadSection of GU Medical OncologyUSC Keck School of Medicine Leader Developmental Therapeutics ProgramUSC Norris Comprehensive Cancer CenterLos Angeles, CA

Sunil Reddy, MDClinical Assistant ProfessorMedicine-OncologyStanford Cancer CenterStanford, CA

Jonathan Riess, MDAssistant ProfessorUC Davis School of MedicineSacramento, CA

Sarmad Sadeghi, MD, PhDAssistant Professor, University ofSouthern CaliforniaDivision of OncologyNorris Comprehensive Cancer CenterLos Angeles, CA

Ravi Salgia, MD, PhDProfessor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Sandy Srinivas, MDAssociate ProfessorStanford University School of MedicineStanford, CA

Joseph Tuscano, MDProfessor of Medicine, Division of Hematology and Oncology, UC Davis School of MedicineUC Davis Comprehensive Cancer CenterSacramento, CA

Przemyslaw Twardowski, MDAssociate Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

Jeff Weitzel, MDProfessor of Oncology & Population SciencesChief, Division of Clinical Cancer GenomicsCity of Hope Comprehensive Cancer CenterDuarte, CA

Yuan Yuan, MD, PhDAssistant ProfessorDepartment of Medical Oncology &Therapeutic ResearchCity of Hope Comprehensive Cancer CenterDuarte, CA

13th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”COURSE DESCRIPTIONThis conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVESAfter participating in this educational activity, you should be able to:

• Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of various tumor types, and identify specific opportunities for therapeutic intervention.

• Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of patients with cancer.

• Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of patients with cancer.

• Discuss new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCEThis program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENTThis course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently, improve patient outcomes.

ACCREDITATIONThe Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this live educational activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSUREThe Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.

13th Annual California Cancer Consortium Conference “Recent Advances and New Directions in Cancer Therapy”

11:30 am Registration & Visit Exhibits

12:45 pm - 1:55 pm Product Showcase Lunch (Non CME)2:00 pm Welcome and Introductions

Session 1: Everything Old is New Again: Targeting DNA Repair Pathways in OncologyChairs: Primo Lara (UC Davis) and Edward Newman (City of Hope)

2:15 pm DNA Repair (PARP, Wee1, ATM, ATR, etc) as a Therapeutic Target Jeff Weitzel, City of Hope

2:35 pm Question-and-Answer Session

2:40 pm BER Inhibitors (TRC102) Marianna Koczywas, City of Hope

3:00 pm Question-and-Answer Session

3:05 pm ATR Inhibition (VX-970) Sumanta Pal, City of Hope

3:25 pm Question-and-Answer Session

3:30 pm Novel Cytotoxics in Development Sarmad Sadeghi, USC

3:50 pm Question-and-Answer Session

3:55 pm – 4:25 pm Product Showcase (Non-CME )

4:25 pm – 4:40 pm Refreshment Break; Visit Exhibits

Session 2: Clinical Trial DesignChairs: Susan Groshen (USC) and Paul Frankel (City of Hope)

4:40 pm Design of Phase I Trials 101: Beyond Modified Fibonacci (CRM, TITE-CRM, etc) Shivaani Kummar, Stanford

5:00 pm Question-and-Answer Session

5:05 pm Design of Phase 2 Trials 101: Promise and Pitfalls of Interim Analysis Susan Groshen, USC

5:25 pm Question-and-Answer Session

5:30 pm Statistical Considerations for Molecular Correlative Studies in Phase I and II Trials Jeff Longmate, City of Hope

5:50 pm Question-and-Answer Session

5:55 pm Roundtable Discussion Moderator: Edward Newman (City of Hope) Participants: Jeff Longmate, Paul Frankel, Susan Groshen, Shivaani Kummar

6:15 pm Adjourn for the Day

6:30 pm – 7:30 pm Welcome Reception

7:30 pm – 9:00 pm Product Showcase – Dinner (Non CME)

FRIDAY, AUGUST 18th, 2017

CONFERENCE AGENDA

6:30 am Registration, Breakfast, & Visit Exhibits

6:45 am – 7:55 am Breakfast & Product Showcase (Non-CME)

8:00 am Welcome and Introduction

Session 3: Cancer ImmunotherapyChair: Tanya Dorff (USC) and Mamta Parikh (UC Davis)

8:05 am Overview of Immuno-Oncology Arta Monjazeb, UC Davis

8:25 am Question-and-Answer Session

8:30 am Measuring Immune Response in Tumors Peter Lee, City of Hope

8:50 am Question-and-Answer Session

Session 4: Malignant MelanomaChair: Edward Newman (City of Hope) and Christiane Querfeld (City of Hope)

8:55 am State of the Art: Immunotherapy Kim Margolin, City of Hope

9:15 am Question-and-Answer Session

9:20 am State of the Art: Targeted Therapies (BRAF, etc) Sunil Reddy, Stanford

9:40 am Question-and-Answer Session

9:45 am – 10:30 am Refreshment Break; Visit Exhibits9:55 am – 10:25 am Product Showcase (Non-CME)

Session 5: Lung CancersChairs: Erminia Massarelli (City of Hope) and Jonathan Riess (UC Davis)

10:30 am Evolution and Increasing Complexity of Therapeutic Decision-Making in Advanced NSCLC David Gandara, UC Davis

10:50 am Question-and-Answer Session

10:55 am Small Cell Lung Cancer: State of the Art 2017 Ravi Salgia, City of Hope

11:15 am Question-and-Answer Session

11:20 am EGFR Inhibitors in Lung Cancer Jonathan Riess, UC Davis

11:40 am Question-and-Answer Session

11:45 am ALK, MET, RET, NTRK Inhibitors in Lung Cancer <TBA>

12:05 pm Question-and-Answer Session

12:10 pm Lunch Break, Product Showcase, Visit Exhibits

12:20 pm – 1:20 pm Product Showcase (Non-CME)

1:20 pm Visit Exhibits

SATURDAY, AUGUST 19th, 2017

CONFERENCE AGENDACONFERENCE AGENDA

Session 6: Hematologic MalignanciesChair: Guido Marcucci (City of Hope) and Joseph Tuscano (UC Davis)

1:30 pm New Developments in Acute Lymphocytic Leukemia Brian Jonas, UC Davis

1:50 pm Question-and-Answer Session

1:55 pm New Developments in Acute Myeloid Leukemia Kevin Kelly, USC

2:15 pm Question-and-Answer Session

2:20 pm State of the Art: Malignant Lymphomas Robert Chen, City of Hope

2:40 pm Question and Answer Session

2:45 pm New Developments in Plasma Cell Dyscrasias Joseph Tuscano, UC Davis

3:05 pm Question and Answer Session

3:10 pm – 3:20 pm Refreshment break, Visit Exhibits

Session 7: Genitourinary MalignanciesChairs: Mamta Parikh (UC Davis) and Samrad Sadeghi (USC)

3:20 pm Castration Resistant Prostate Cancer Przemyslaw Twardowski, City of Hope

3:40 pm Question-and-Answer Session

3:45 pm Renal Cell Carcinoma Sandya Srinivas, Stanford

4:05 pm Question-and-Answer Session

4:10 pm Advances in Urothelial Cancer David Quinn, USC

4:30 pm Question and Answer Session

Session 8: Gastrointestinal MalignanciesChairs: Vincent Chung (City of Hope) and Afsaneh Barzi (USC)

4:35 pm New Developments in Esophagogastric and Pancreatic Cancers Edward Kim, UC Davis

4:55 pm Question-and-Answer Session

5:00 pm New Developments in Colorectal Cancer Marwan Fakih, City of Hope

5:20 pm Question-and-Answer Session

5:25 pm Update on Immunotherapy in GI Cancer Anthony El-Khoueiry, USC

5:45 pm Question-and-Answer Session

5:50 pm Adjourn for the Day

CONFERENCE AGENDA

6:30 am Registration, Refreshments & Visit Exhibits

6:45 am – 7:55 am Breakfast & Product Showcase (Non-CME)

8:00 am Introduction

Session 9: Breast CancerChair: Yuan Yuan (City of Hope) and Helen Chew (UC Davis)

8:10 am Adjuvant Therapy in Breast Cancer: State of the Art Mark Pegram, Stanford

8:30 am Question-and-Answer Session

8:35 am Metastatic Breast Cancer Helen Chew, UC Davis

8:55 am Question-and-Answer Session

9:00 am – 9:45 am Refreshment Break & Visit Exhibits

9:10 am – 9:40 am Product Showcase (Non-CME)

Session 10: Solid Tumors, New Therapeutics, and New DiagnosticsChairs: Edward Newman (City of Hope) and Primo Lara (UC Davis)

9:45 am Head and Neck Cancer: New Developments A. Dimitrios Colevas, Stanford

10:05 am Question-and-Answer Session

10:10 am Soft Tissue Sarcoma: Evolving Standards of Care James Hu, USC

10:30 am Question-and-Answer Session

10:35 am Gynecologic Malignancies: New Approaches in 2017 Mihaela Cristea, City of Hope

10:55 am Question-and-Answer Session

11:00 am Cell Therapy for Gynecologic Cancers Oliver Dorigo, Stanford

11:20 am Question-and-Answer Session

11:25 am Circulating Tumor DNA: Clinical Applications Philip Mack, UC Davis

11:45 am Question-and-Answer Session

11:50 am Closing and Adjourn

CONFERENCE AGENDA

SUNDAY, AUGUST 20th, 2017

The Langham Hotel, Pasadena has been recognized with numerous accolades and awards from some of the top luxury hotel, meetings, dining and leisure travel publications in the world. The Los Angeles’ original getaway. Experience the iconic landmark hotel located in charming Pasadena, just minutes from Downtown.

Historical Property tours are offered daily at 2:00pm, led by our Service Stylists; please meet in the Lobby. Tours are also pre-reservable through our Concierge Desk at (626) 568-3900, or download a self-guided Historical Property Tour. See over 100 years of Langham Huntington history by downloading our Historic Timeline.

The Langham is offering special rates during this conference of $219 ++ for Deluxe King accommodations. Cut off date to make reservations is July 17, 2017, after that date reservations are based on hotel availability.

FOR RESERVATION CONTACT the in-house reservation team at 1-800-591-7481 and reference the group name (California Cancer Conference) or group code (MEC081817).

CONFERENCE MANAGEMENTMEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

6619 South Dixie Highway, #341Miami, FL 33143

Telephone: 305.663.1628Fax: 305.675.2718

Website: www.meccinc.comEmail: tvalls@meccinc.com

Register online at www.meccinc.com under the conference information and registration tab.

THE LANGHAM HOTELPASADENA, CA1401 South Oak Knoll AvenuePasadena, CA 91106(626) 568-3900

Reservations: 1-800-591-7481

HOTEL INFORMATION

Name _______________________________________________ Degree ______________

Address __________________________________________________________________

Telephone (____) ____________________________ Fax (____) _____________________

Email Address _____________________________________________________________

Specialty _________________________________________________________________

TYPE OF PRACTICE: o Private o Academic o Hospital o Other

REGISTRATION FEE: o $175 Physician o $ 90 Nurse, Nurse Practitioner, Resident, Fellow, Students, Non-physician researchers and staff (e.g., CRAs) o $300 Industry Professional

Refunds must be provided in writing prior to July 8th, 2017. A $50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

I authorize MECC to charge my credit card i/a/o $__________ for the registration of this course using the following credit card.

Name as it appears on the card _____________________________ Exp. Date ___________

Card number __________________________________________ CVV Code: ________

thorized signature ________________________________________________________

For those requiring special assistance, contact MECCat 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2017

Registration Form

13th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”August 18-20, 2017, The Langham Hotel, Pasadena, CA

Register online at www.meccinc.com or fax to 305.675.2718

Mee

ting

s, E

vent

s an

d C

onfe

renc

e C

oord

inat

ors,

Inc

.P.

O. B

ox 4

3037

6M

iam

i, FL

332

43-0

376

____

____

____

_PR

ST S

TDU

S Po

stage

PA

IDM

iami,

FLPe

rmit

No.

142

9

13th

ANN

UAL

CAL

IFO

RN

IA C

ANC

ER C

ON

SORT

IUM

CO

NFE

REN

CE

“Rec

ent A

dvan

ces a

nd N

ew D

irecti

ons i

n Ca

ncer

The

rapy

”

Augu

st 1

8-20

, 201

7Th

e Lan

gham

Hot

el, P

asad

ena,

CA